NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ
Post# of 73
(Total Views: 234)
Posted On: 12/07/2021 3:37:41 PM
NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Initial Shipment of CGM Devices to MySugarWatch Licensee
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited, previously DB Ethitronix Limited. According to the update, MySugarWatch will sell the CGM under the brand MySugarWatch(R) and has developed a subscription-based diabetes coaching and management service to be provided alongside the CGM and device sensors primarily targeting those with type 2 diabetes. “This initial shipment of sugarBEAT CGM devices to our U.K. licensee allows the company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” Nemaura CEO Dr. Faz Chowdhury said in the news release. “Starting in the U.K., patients with type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence and outcome. We look forward to the introduction of sugarBEAT to patients across the world, as we continue our mission of developing and introducing ground-breaking health care solutions for many of the greatest health care challenges seen across the globe.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced that it has completed its initial shipment of sugarBEAT(R) continuous glucose monitor (“CGM”) devices to its U.K. licensee, MySugarWatch Limited, previously DB Ethitronix Limited. According to the update, MySugarWatch will sell the CGM under the brand MySugarWatch(R) and has developed a subscription-based diabetes coaching and management service to be provided alongside the CGM and device sensors primarily targeting those with type 2 diabetes. “This initial shipment of sugarBEAT CGM devices to our U.K. licensee allows the company to now recognize revenue for the first time in our corporate history and is a true milestone in our development and growth,” Nemaura CEO Dr. Faz Chowdhury said in the news release. “Starting in the U.K., patients with type 2 diabetes can now benefit from a less invasive glucose monitoring option that should improve patient lifestyle, adherence and outcome. We look forward to the introduction of sugarBEAT to patients across the world, as we continue our mission of developing and introducing ground-breaking health care solutions for many of the greatest health care challenges seen across the globe.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)